All information was based on self-reporting and included number of prescribed antihypertensive drugs, trade names of all prescribed drugs along with the drug class, doses in milligrams (mg), frequency per day, duration of intake in months, time of intake of the drug (morning, afternoon, evening), and any side effects associated with the drug.
A total of 31 cases declared to have changed their food intake ⩾12 months before interview because of gastrointestinal symptoms, and were excluded from this analysis.
Two other patients at our institution had interrupted lenalidomide treatment after prolonged intake (at months 24 and 13, respectively) in complete hematologic and cytogenetic remission for reasons other than an adverse event.
The present study demonstrated that the participants in the intervention group with normal and above normal pre-pregnancy BMI had similar calorie intakes a months after the intervention (2 016 kcal/d versus 1 986 kcal/d).
The sample produced a mean weight loss of 6.5±5.2 kg (range –27.8 to +5 kg) and this was associated with reported change in energy intake (P=0.002, 3 months; P=0.009 12 months) estimated at about –2000 kJ/day (P<0.001, time effect; Table 2).
The median duration of imatinib mesylate intake was 8.0 months (range 5~20 months).
Data collection took place at baseline (directly following the EoP intake), after 6 months (shortly after completion of EoP) and after 12 months (follow-up measurement 6 months after completion of EoP) for both the intervention group and the control group.
Statistical analyses examined the associations between the 'junk' pattern score and mean weekly NMES intake at 81 months, and each SDQ score at 97 months.
Median cumulative length of ABZ intake was 12.2 months (IQR 4.2-38.3), while median WW observational period was 48.8 months (IQR 30.8-116.9).
This study has shown that neither junk food diet nor NMES intake at 81 months increase the risk of development of behavioural problems over the next 16 months.
